The European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trials were supposed to help resolve the dispute over the value of PSA testing, but they ultimately arrived at opposite conclusions. Here, KLK3 is linked to prostate carcinoma.